Shingles vaccine maker Curevo lands $110M, adds biotech vets to board
Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B ...
Fierce Biotech4h
Curevo rounds up $110M to challenge GSK’s Shringrix, nabs Moncef Slaoui to lead board
In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...
What's the future of health in the US? Experts offer some answers during SXSW in Austin
Let's talk about menopause, AI, Alzheimer's and more health topics at South by Southwest, with some lab brains and nature ...
Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine
Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...
The Canadian Press on MSN13h
Today-History-Mar17
Today in History for March 17: ...
AI drug discovery startup is Boston's latest 'unicorn'
A Boston drug discovery company that uses AI has hit unicorn valuation. It uses transformer diffusion models, which its CEO ...
Endpoints News7h
Cure­vo gets $110M for a shot against Shin­grix, gets Mon­cef Slaoui and Tal Zaks on board
Curevo Vaccine raises $110M Series B for shingles vaccine trial extension, adds Moncef Slaoui as board chair and Moderna's ...